Mackies back in townTheratechnologies (TSE:TH) was upgraded by research analysts at Mackie from an outperform rating to a strong-buy rating in a report issued on Wednesday, Marketbeat reports. The brokerage presently has a C$1.80 target price on the stock, down from their previous target price of C$3.50. Mackies price target points to a potential upside of 12.50% from the stocks previous close. Shares of Theratechnologies (TSE:TH) opened at 1.60 on Wednesday. The stocks 50 day moving average price is $1.78 and its 200-day moving average price is $1.85. Theratechnologies has a 52-week low of $0.32 and a 52-week high of $2.72. The firms market cap is $104.98 million. Theratechnologies Inc. is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to encourage healthy ageing. The product, EGRIFTA, of the Companys is employed for the reduction of excessive abdominal fat in human immunodeficiency virus (TSE:TH)-infected patients. EGRIFTATM is available in the United States as a once-daily two unit dose (two vials, each containing 1 milligram of tesamorelin) of sterilized lyophilized powder to be reconstituted with sterile water. Its subsidiaries comprise Theratechnologies Intercontinental Inc., Theratechnologies Europe Inc., Theratechnologies Canada Inc. and Pharma-G Inc.